All current vaccines for COVID-19 utilize ancestral SARS-CoV-2 spike with the goal of
generating protective neutralizing antibodies. The recent emergence and rapid spread of …

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibody
neutralization response and its evasion by emerging viral variants and variant of concern …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …

Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19
and are especially important in high-risk individuals where vaccination is not an option …

Toward eradicating the COVID-19 pandemic, vaccines that induce high humoral and cellular
immune responses are essential. However, SARS-CoV-2 variants have begun to emerge …

Transmission of SARS-CoV-2 is uncontrolled in many parts of the world; control is
compounded in some areas by the higher transmission potential of the B. 1.1. 7 variant …

The SARS-CoV-2 pandemic has, as of July 2022, infected more than 550 million people and
caused over 6 million deaths across the world. COVID-19 vaccines were quickly developed …

Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and
mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …

Although neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of
most COVID-19 vaccines and being developed as therapeutics, escape mutations could …

Abstract SARS-CoV-2 vaccines, administered to billions of people worldwide, mitigate the
effects of the COVID-19 pandemic, however little is known about the molecular basis of …